Our data show that bTAM preferentially express growth factors and cytokines known to promote ovarian cancer growth, progression and relapse, such as CCL18, but also factors, which have previously not been implicated in ovarian cancer progression, e.g. KITLG and complement factors. This evidence concerns the gene CCL18 and ovarian carcinoma.